Archived explainer. For the current picture see today's ERAS page.
ERASCA INC (ERAS) is down -10.37% in the latest session. Our newswire has captured 1 story on ERAS across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 73/100).
ERAS stock fell 10.37% to $19.05 in morning trading on Thursday, reversing a recent rally that had pushed the shares to a new 52-week high earlier in the week. The decline followed a sharp intraday selloff that began after the stock opened lower and continued throughout the session. The move came amid a backdrop of recent corporate activity including a public offering and updated clinical trial progress.
Erasca’s shares opened at $21.11, a 0.7% gap down from the prior close of $21.26. The stock reached an intraday high of $21.11 at 7:00 AM ET but declined steadily throughout the session, hitting a low of $18.98 at 2:25 PM ET. The stock closed the session at $19.05, a drop of 10.37% from its previous close. The volume of 3.3 million shares traded was 0.5 times the 3-month daily average, indicating limited liquidity during the move. The decline followed a recent 11.9% gain over the previous 8 sessions, which had lifted the stock from $18.36 to $20.55.
The company has been in the news recently for its updated progress on a cancer treatment candidate for RAS-mutant solid tumors. Earlier in the week, the stock had surged 8.94% on Tuesday after positive clinical trial results. Bank of America Securities also raised its price target for the stock to $18 while maintaining a neutral stance. Additionally, the company has announced a $500 million common stock offering and priced an upsized public offering of 31,428,572 shares at $17.50 per share.
Investors should continue to monitor the company’s upcoming corporate actions and clinical trial developments. No earnings date is scheduled in the immediate future, but coverage breadth and investor sentiment will remain key factors to watch as the stock trades near its 52-week range of $1.33 to $24.28.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, strengthening investor confidence that the drug could become a potential treatment option for difficult-to-treat RAS-mutant cancers. Based on data from the phase 1 clinical […]
More on ERAS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ERAS move explainers: 2026-07-16 · 2026-07-14